8-K: SANUWAVE Health Announces Preliminary Q1 2025 Revenue Results, Reporting Record Highs

SANUWAVE Health reports preliminary Q1 2025 revenues between $9.1 million and $9.3 million, marking a 57% to 61% increase compared to Q1 2024 and the highest Q1 revenue in company history.

Summary

• SANUWAVE Health announced preliminary revenue results for the first quarter of 2025.
• Revenues are expected to be between $9.1 million and $9.3 million, representing a 57% to 61% increase compared to Q1 2024.
• This marks the highest Q1 quarterly revenues in the company's history.
• UltraMIST revenues increased by more than 65% compared to Q1 2024 and accounted for approximately 99% of total revenues.
• The company plans to release full Q1 results around May 9, 2025.
• All manufacturing for the UltraMIST system and its applicators is performed domestically, mitigating concerns about tariff impacts.

Sentiment

Score: 8

Explanation: The document presents a positive outlook with strong revenue growth and confidence in future performance. The emphasis on domestic manufacturing also mitigates potential risks.

Positives

• The company achieved its highest Q1 quarterly revenues in its history.
• There was a significant increase in revenue compared to the previous year.
• UltraMIST product line is performing very well.
• The company does not anticipate any significant effects on production from the current tariff situation.

Risks

• The preliminary revenue results are based on management's initial analysis and may be subject to adjustments.
• Forward-looking statements are subject to risks and uncertainties, including regulatory oversight and competition.

Future Outlook

The company anticipates 2025 to be a breakout year and plans to release full Q1 results around May 9, 2025, providing a more complete update on quarterly performance and future plans.

Management Comments

• CEO Morgan Frank stated that Q1 was a transition quarter due to a new head of sales and sales force restructuring, but the team managed it without missing a beat.
• CEO Morgan Frank stated that the pipeline remains robust and consistent with 2025 being a breakout year for Sanuwave.

Industry Context

The announcement highlights SANUWAVE's position as a leading provider of FDA-approved wound care products, particularly in the regenerative medicine space. The emphasis on domestic manufacturing is relevant given current global trade uncertainties.

Comparison to Industry Standards

• Comparing SANUWAVE's growth to competitors like Integra LifeSciences or Organogenesis, which also operate in the wound care market, would provide a benchmark.
• For example, if Integra LifeSciences reported a Q1 revenue growth of 15%, SANUWAVE's 57%-61% growth would be significantly higher.
• Similarly, comparing UltraMIST's performance to similar products from competitors like Misonix's SonicOne would offer insights into market share and product adoption.

Stakeholder Impact

• Shareholders can expect positive returns if the company continues to perform well.
• Employees may benefit from the company's growth and success.
• Customers will continue to have access to the company's wound care products.

Next Steps

• The company plans to release its full Q1 results on or around May 9, 2025.
• The company plans to provide a more complete update on its quarterly performance and future plans and guidance on or around May 9, 2025.

Key Dates

Keywords

SANUWAVE Health, revenue, UltraMIST, wound care, financial results, Q1 2025